You are here
If we don't have the booster campaign early enough we might not be in a great spot in the fall --Moderna CEO
Primary tabs
COVID-19: 'We might not be in a great spot in the fall': Moderna CEO
While the U.S. waits on funding and for the U.S. Food and Drug Administration (FDA) to decide on which virus strain to attack through boosters, Moderna and other vaccine companies are anticipating waning immunity to become a concern.
"This virus is not getting less infectious," Moderna CEO Stéphane Bancel told Yahoo Finance. "As you see more and more infectious variants ... We are not done with this virus mutating," he said.
The biggest risk in the fall, if boosting is delayed, is the potential for hospitals to fill up with those that are the most vulnerable all over again, Bancel said.
The increased circulation from the intersection of waning immunity and a more transmissible variant, as is being observed with more Omicron subvariants in the U.S. and abroad, is the real risk, he said.
"We have a risk in the fall — if we don't have the booster campaign early enough —that we might not be in a great spot in the fall," Bancel said.
...
Meanwhile, the World Health Organization has been pushing the company to share its vaccine recipe even as it fails to order more doses through the COVAX facility program for lower and middle income countries.
Moderna said during its annual shareholder meeting that it is selling its vaccine as low as $7 per dose to those countries and has waived its patent enforcement of the vaccine, in addition to its plans for a plant in Kenya in the coming years. ..
Comments
- [global-health][5 other groups] If we don't have the...
My chagrin is below.
Language matters and the linguistic lexicon below is not helpful at a hyper-local level. Not happy I am.
Be Mindful, Be Active and Be Well!
Ed
Edward D Shanshala II, MSHSA, MSEd
Chief Executive Officer
Ammonoosuc Community Health Services, Inc.
Your Community Health Partner for Life
25 Mt. Eustis Road
Littleton, NH 03561
603-991-7756 (cell 24/7)
https://ammonoosuc.org/
ACHS YouTube channel
From: noreply@m.resiliencesystem.org <noreply@m.resiliencesystem.org>
Sent: Friday, May 6, 2022 10:11 AM
To: Global Health <global-health@m.resiliencesystem.org>; Health - US <health-us@m.resiliencesystem.org>; Medical - global <medical-global@m.resiliencesystem.org>; New Hampshire RAC Executive Team <newhampshire-rac-et@m.resiliencesystem.org>; RAC Vaccines
and Vaccination Group <rac-vaccination@m.resiliencesystem.org>; Vaccines <vaccines_global@m.resiliencesystem.org>
Subject: [EXTERNAL] - [global-health][5 other groups] If we don't have the booster campaign early enough we might not be in a great spot in the fall --Moderna CEO
COVID-19:
'We might not be in a great spot in the fall': Moderna CEO
While the U.S. waits on funding and for the U.S. Food and Drug Administration (FDA) to decide on which virus strain to attack through boosters, Moderna and other vaccine companies are anticipating waning immunity to become a concern.
"This virus is not getting less infectious," this language is inelegant in that “infectious” conflates the Ro transmissibility with morbidity and mortality. It is important to de-conflate. It is exactly this lack of linguistic thoughtfulness
that drives the populations distrust and confusion. As a CEO having been a research I am not amused by such a high paid official to lack this level of skill harumph!
Moderna CEO Stéphane Bancel told Yahoo Finance. "As you see more and more infectious variants ... We are not done with this virus mutating," he said.
The biggest risk in the fall, if boosting is delayed, is the potential for hospitals to fill up with those that are the most vulnerable all over again, Bancel said.
The increased circulation from the intersection of waning immunity and a more transmissible variant, as is being observed with more Omicron subvariants in the U.S. and abroad, is the real risk, he said.
"We have a risk in the fall — if we don't have the booster campaign early enough —that we might not be in a great spot in the fall," Bancel said.
...
Meanwhile, the World Health Organization has been pushing the company to share its vaccine recipe even as it fails to order more doses through the COVAX facility program for lower and middle income countries.
Moderna said during its annual shareholder meeting that it is selling its vaccine as low as $7 per dose to those countries and has waived its patent enforcement of the vaccine, in addition to its plans for a plant in Kenya in the coming years. ..
--
Full post:
https://resiliencesystem.org/if-we-dont-have-booster-campaign-early-enough-we-might-not-be-great-spot-fall-moderna-ceo
Manage my subscriptions: https://resiliencesystem.org/mailinglist
Stop emails for this post:
https://resiliencesystem.org/mailinglist/unsubscribe/22156
ATTENTION! The above email is from an external source. Please do not open attachments or click links from an unknown sender or of those with a suspicious origin.
Not sure? Reach out to IT (x8238) before you click the link.
Confidentiality Notice: Information received in this e-mail is intended only for the use of the addressee (s) listed above. Any attachment (s) or links provided are privileged and confidential and may contain information that is protected by law. If
you have received this e-mail in error, we respectfully ask that you please contact the sender and delete the original message.